Latest Breaking News On - Clin hypertension - Page 1 : comparemela.com

Idorsia Pharmaceuticals Ltd: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Idorsia Pharmaceuticals Ltd: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalDennis riedlJ physiol pharmacolClozelm aprocitentanAndrewc weissJean paul clozelIdorsia ltdEuropean commissionHead of investor relations corporate communicationsSwiss exchangeEuropean union member statesIdorsia pharmaceuticals ltdCommittee for medicinal products humanEuropean medicines agencyCommittee for medicinal products human use

JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension

Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for JERAYGO™ as the first and only endothelin receptor.

Switzerland generalUnited statesJean paul clozelClozelm aprocitentanJ physiol pharmacolAndrewc weissEuropean medicines agencyEuropean commissionEuropean unionCommittee for medicinal products human useSwiss exchangeDrug administrationEuropean union member statesIdorsia ltdIdorsia pharmaceuticals ltdCommittee for medicinal products human

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalJ physiol pharmacolGeorge bakrisClozelm aprocitentanAlberto gimonaMarkus schlaichIrvine pageArterioscler thromb vascAndrewc weissAmerican heart associationIdorsia ltdNational committeeSwiss exchangeUniversity of chicago medicineNational kidney foundation

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalClozelm aprocitentanArterioscler thromb vascJ physiol pharmacolAlberto gimonaAndrewc weissIrvine pageMarkus schlaichGeorge bakrisAmerican society of nephrologyAmerican society of hypertensionIdorsia pharmaceuticals ltdUniversity of chicago medicineHypertension centerUniversity of chicago school medicine

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalGeorge bakrisIrvine pageJ physiol pharmacolClozelm aprocitentanArterioscler thromb vascAlberto gimonaMarkus schlaichAndrewc weissNational kidney foundationHypertension centerAmerican society of nephrologyIdorsia ltdUniversity of chicago medicineHead of investor relations corporate communications